What moved LLY and why it matters
Eli Lilly’s latest reported catalyst is the October 29, 2026 third-quarter update: revenue rose 39% year over year to $24.4 billion, adjusted EPS came in at $7.48, and management lifted full-year 2026 revenue guidance to $91.0 billion to $92.0 billion while also raising underlying non-GAAP EPS guidance. That matters because the market is still anchoring the stock to execution in obesity and diabetes, where Mounjaro and Zepbound remain the main revenue engines. citeturn0search0
RBC Capital reiterated an Outperform rating and a $1,600 target on November 17, 2026, while Barclays raised its target to $1,550 on November 16, 2026. Stockanalysis.com, citing 31 analysts polled by S&P Global, shows a consensus Buy rating and an average target of $1,470, with a wide range from $940 to $1,700. That spread says the market is still rewarding Lilly’s growth profile, but the path higher is not being priced as a straight line. citeturn0search1turn0search2turn0search3
Technical picture: constructive pullback, not a clean breakout
At $1,356.25, LLY is trading below the 7-day SMA of $1,399.02, the 20-day SMA of $1,403.22, the 12-day EMA of $1,393.00, and the 26-day EMA of $1,374.24. That is a short-term distribution pattern, but the stock remains above the 50-day SMA of $1,306.70, which keeps the medium-term trend intact. citeturn0search4
Momentum is soft rather than broken. RSI at 46.54 is neutral, MACD histogram is flat at 0.0000, and stochastic readings are depressed, with %K at 9.54 and %D at 7.64. In plain terms, the stock has lost upside momentum, but the indicator mix does not yet confirm a full trend reversal. citeturn0search4
Price is also sitting near the lower Bollinger Band at $1,334.34, with %B at 0.1590, which signals the shares are near lower-band support rather than stretched on the upside. The key levels from the daily structure are clear: immediate resistance at $1,378.67, stronger resistance at $1,401.10, immediate support at $1,337.91, and strong support at $1,319.58. citeturn0search4
What Binance Futures is signaling
Binance perpetual futures show a neutral funding rate, which means there is no obvious crowding cost on either side. Open interest is 2,198 contracts, with a daily open interest value of $3.14 million and a 24-hour increase of 5.49%, so new positioning is being added even as price slips. citeturn0search4
The positioning mix is mildly defensive: Binance global accounts show 46.3% long versus 53.7% short, and top-trader accounts are even more skewed at 44.1% long versus 55.9% short. The taker buy/sell ratio of 1.4854, however, shows aggressive buying pressure in the latest 1-hour window. That combination usually points to a market that is trying to stabilize, but not yet in agreement on direction. citeturn0search4
Scenario lens
If LLY can reclaim the $1,378.67 to $1,401.10 resistance band, the market would be signaling that the pullback is being absorbed and that post-earnings support is still intact. If it fails to hold $1,337.91, the next test is the $1,319.58 strong support area, which also sits close to the stock’s 50-day average and would be the more important line for trend followers. citeturn0search4
The cleanest read right now is that Eli Lilly still has a strong fundamental story, but the short-term tape is consolidating around recent gains. Until price reclaims the moving-average cluster, the burden is on bulls to prove the post-earnings strength is more than a one-way move.



